[go: up one dir, main page]

WO2017030388A1 - Composition pour le traitement de lésions cutanées - Google Patents

Composition pour le traitement de lésions cutanées Download PDF

Info

Publication number
WO2017030388A1
WO2017030388A1 PCT/KR2016/009107 KR2016009107W WO2017030388A1 WO 2017030388 A1 WO2017030388 A1 WO 2017030388A1 KR 2016009107 W KR2016009107 W KR 2016009107W WO 2017030388 A1 WO2017030388 A1 WO 2017030388A1
Authority
WO
WIPO (PCT)
Prior art keywords
wound
skin
collagen
glycerin
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/009107
Other languages
English (en)
Korean (ko)
Other versions
WO2017030388A9 (fr
Inventor
이상철
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201680019591.4A priority Critical patent/CN107427561A/zh
Publication of WO2017030388A1 publication Critical patent/WO2017030388A1/fr
Anticipated expiration legal-status Critical
Publication of WO2017030388A9 publication Critical patent/WO2017030388A9/fr
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Definitions

  • the present invention relates to a composition for treating skin wounds, and more particularly, to a composition for treating skin wounds, which can alleviate and heal pain in skin wounds such as burns, traumas, wounds and pressure sores.
  • Skin is an important organ with the largest surface area in the body, and if the skin is extensively damaged, it may lose its life due to dehydration.
  • the skin must be resistant to physical irritation and elasticity because it serves to protect against and to prevent dehydration and to regulate body temperature by inhibiting evaporation of the human body.
  • the wound is inevitable skin transplantation in the case of wounds that are not primary suture Since the scars are left behind, it is necessary to promptly treat the wound in order to repair the damaged skin tissue, and it is essential to dress and treat the secondary to minimize various side effects.
  • the damaged skin or mucous membrane contains dying cells, microorganisms, contaminants, Cells, microorganisms and contaminants contained must be removed or degraded, whereby protease is secreted to degrade the cells, microorganisms and contaminants.
  • MMPs matrix metalloproteins
  • intercellular matrix MMPs: matrix metalloproteins
  • MMPs matrix metalloproteins
  • proteins proteins, collagen, elastin hyaluronic acid, and the like, which fill a space between cells.
  • intercellular matrices are of different types, they require different types of neutralizing specific polyphenols. These are two specific plant extracts that are not related to each other, thereby stopping the breakdown of the intercellular matrix and having a synergistic effect on cell growth. Thus, different types of intercellular matrix (MMPs) can be converted into two neutralizing polyphenols or polysaccharides. Alternatively, it is possible to have three types.
  • the vegetable extract (herb extract) uses tannic acid, which has been used for all leather since Egyptian times, because tannic acid has the ability to bind proteins.
  • the tannic acid is a component in the persimmon persimmon, and in terms of molecular structure, polyphenols and polysaccharides are attached, and procyanidine or ansocyanidin in a dark-colored fruit with antioxidant activity. Also called (anthocyanidine).
  • Herbal extracts that have the ability to bind to proteolytic enzymes are a type of Alchemilla vulgaris, and other extracts bind to viruses or other proteins. Therefore, if glycerin contains other herbal extracts, it is effective for other types of wounds.
  • the plant extract may neutralize proteolytic enzymes by combining polyphenols and polysaccharides known to precipitate large molecules with proteolytic enzymes.
  • the polyphenols and polysaccharides have a strong affinity for proteins, and some polyphenols or polysaccharides bind to bacteria or viral proteins to reduce the release of toxic substances of infection, microbial origin, and cell growth. It helps to promote.
  • Alchemilla Vulgaris is a herb that has been used for the treatment of gastrointestinal disorders and wounds since the Middle Ages, and Mimosa (Timosa Tenuiflora) has traditionally been used to treat skin wounds, burns, and oral wounds. Both herbal extracts are rich in Procyanidins.
  • procyanidins promote wound healing
  • MMPs cellular degrading enzymes
  • Collagen is also used for wound healing, which is a fibrous protein found in most connective tissues such as skin, muscles and tendons, especially in animals and humans. When collagen comes into contact with blood, platelets aggregate to collagen and maintain coagulation factors that are released together with plasma to finally form fibrin and thrombus to act as a hemostatic action.
  • the first formulation is a powder.
  • Collagen is the first protein to be temporarily formed in the empty space during the wound treatment process, and despite the expectation that it will promote wound healing, the powder formulation has been limited in use due to some disadvantages.
  • Sponge-type collagen products have been developed to compensate for these drawbacks, but this formulation also caused other drawbacks.
  • the sponge-like product was covered on the wound area, the wound treatment did not have much effect to promote the wound treatment because it could not be in close contact with the wound and an empty space was created.
  • This product was prepared by mixing saline with collagen powder, paste or paste, and applying it closely to the wound surface to easily remove it from the wound after hemostasis and hemostasis.
  • the prior art is not only used as a hemostatic agent by mixing saline with collagen to be in close contact with the wound surface, but there is an insufficient problem of promoting wound healing, and moisture is easily evaporated. There is a problem that the pain relief effect is low and dries easily.
  • An object of the present invention to solve the above problems is to discharge the exudate from the inside of the wound, to remove microorganisms and other contaminants, to inhibit proteolytic enzymes to neutralize their activity by inhibiting the decomposition of the matrix cell growth of the wound site And not only to promote treatment, but also to increase the density by adding collagen to increase the blocking effect with the air to increase the pain relief effect.
  • Means of the present invention according to the solution of the above problem is characterized by mixing 5wt% to 50wt% of powdered collagen in a liquid glycerin containing 2wt% to 5wt% of the vegetable extract to 50wt% to 95wt%.
  • the vegetable extract is Vitis vinifera, Camellia sinensis, Basinium sp., Vaccinium sp., Vaccinoum myrtillus, Alchemilla vulgaris (Alchemilla vulgaris), Mimosa tenuiflora (Mimosa tenuiflora), Echinacea purpura (Echinacea purpura) is characterized in that the extract.
  • the effect of the present invention according to the problem solution means by applying collagen to the skin wound by mixing the glycerin containing the herbal extract, the glycerin applied to the skin wound is discharged exudates from the inside of the skin wound by the high osmotic pressure to the skin wound Sterilizes infected bacteria and other contaminants, herbal extracts promote wound healing by neutralizing proteolytic enzymes that break down the intercellular matrix, repairing the matrix and promoting cell growth, and the collagen accelerates protease faster It not only neutralizes, but also maintains a moisturizing condition by inhibiting water evaporation along with glycerin, which acts as a pain relief and wound cover and promotes wound healing.
  • the present invention is prepared by mixing powdered collagen (collagen) to a liquid glycerin (Glycerol).
  • the glycerin (Glycerol) will contain any one of vegetable extracts or herbal extracts. Preferably it contains a herb extract.
  • the glycerin (Glycerol) can heal the wound with a high moisturizing effect, but only a very small effect of relieving pain by the moisturizing effect.
  • the high concentration of glycerin constricts the cells in the sieve and draws out exudate that moves out of the tissue, and the exudate exudes in combination with the herb extract, which will be described later, to prevent it from entering the sieve.
  • the osmotic pressure is high so that the exudate in the skin moves toward the glycerin, and the herbal extracts in the hypertonic solution do not re-enter the tissue by catching different substances. Therefore, the glycerin is combined with the herbal extract to apply a film on the wound in a state where the viscosity is higher.
  • the glycerin has a high osmotic pressure and a binding force in the form of a polymer, so it exists outside the wound without penetrating into the tissue. Therefore, exudates come out of the tissues along with viruses and contaminants in the wound to clean the wound and facilitate the healing of the wound.
  • the herbal extract is a tannin component present in the plant, and the hydroxyl group and the carbonic acid group of the glycerin are combined to form a precipitate, and each tannin has a different kind of action. Therefore, different types of herbal extracts have different effects, and there are various types of diseases that can be treated.
  • the collagen is a triple helical structure, especially a protein substance with a high hydroproline content, and is insoluble in water, dilute acid and dilute alkali, but dissolves and becomes gelatin. When applied to the wound, it acts as a temporary skin to promote wound healing.
  • liquid glycerin 50wt% to 95wt% of liquid glycerin is mixed with 5wt% to 50wt% of collagen in powder form of 40 to 60 mesh particles, and then prepared by lowering the internal air pressure.
  • the liquid glycerin will contain a vegetable extract.
  • the vegetable extract will contain 2wt% ⁇ 5wt%.
  • the plant extracts are Vitis vinifera, Camellia sinensis, Vaccinium sp., Vaccinoum myrtillus, Alchemilla vulgaris ), Extracts of any one of Mimosa tenuiflora and Echinacea purpura will be used.
  • the present invention preferably contains 90 wt% of the liquid glycerin and 10 wt% of the collagen.
  • the active hypertonic component releases the exudates from the inside of the wound to the outside by glycerin, thereby separating and discharging the microorganisms and other contaminants of the wound outwards, thereby facilitating the healing of the wound.
  • the exudates of microorganisms and contaminants that are separated and discharged to the outside are adsorbed with procyanidin-rich herbal extracts to prevent the exudates from entering the inside again and neutralize their activities by inhibiting proteolytic enzymes that destroy the matrix between cells. Proliferation of the matrix between cells promotes treatment.
  • the collagen is a structural protein constituting the extracellular matrix, a white transparent unbranched fibrils composed of a plurality of sugar protein molecules.
  • the monomer of collagen protein is procollagen, and the procollagen molecule is composed of three long and thin spiral chains.
  • the electron microscope has a stable triple helix space structure of 1.5nm in diameter, 300nm in length and 2.85 ⁇ 105 in relative molecular mass. It is composed of special amino acids.
  • the collagen is a protein that connects cells to cells to form flesh and connective tissue, and exists as an intercellular matrix, and accounts for 25% to 35% of the proteins constituting the body and is a fibrous form of tendons, ligaments, It is present in fibrous tissues such as skin.
  • the collagen is a special protein contained in animal skin or cartilage. It is insoluble in water, extracted by heating in water, and extracted by heating.
  • the steric structure is collapsed to have a denatured protein called gelatin, that is, a liquid upon heating and a solid upon cooling.
  • the collagen when applied to the wound of the skin, it combines the cells of the skin and the cells to promote the thickness of the skin, and also inhibits the evaporation of the moisture of the skin to have a hemostatic action, resistance, disintegration and biocompatibility, clinical hemostasis And promote cell growth to promote wound healing.
  • Example 1 Example 2 Example 3 Glycerin (wt%) + Herb Extract (wt%) 50 90 95 Collagen (wt%) 50 10 5
  • the present invention in the form of a gel prepared in Examples 1 to 3 was treated by applying a thickness of 1 g to the wound of a bed sore patient.
  • the wound area that started treatment with the general treatment showed a deteriorated state even after 10 days once a day, but after 7 weeks of treatment three times a week with the present invention, the wound remains. Neatly healed.
  • the present invention was treated by applying a 1g thickness to the wound of the bed sore patient, as shown in the photo of FIG.
  • the wound site that started treatment with the general treatment showed a worse condition after 11 weeks once a day, but after 4 treatments with the present invention 4 times a week, scars remained relatively little at the wound site. Neatly healed.
  • the present invention was treated by applying a thickness of 1g to the wound of the bed sore patient, as shown in the photo of FIG.
  • the decubitus area that started treatment with a general treatment showed a lot of wounds after 1 week once a week, but as a result of treatment twice a week and 10 times every 5 weeks with the present invention, the wound site was neat. It did not heal, but it was almost healing.
  • the present invention was also treated by applying a thickness of 1 g to the wound of the burn patient, as shown in the photograph of FIG. 4.
  • the burned area that started treatment with the general treatment showed a lot of wounds after 12 weeks once a day, but the treatment with the general treatment was performed twice a week and 10 times in 5 weeks with the present invention.
  • the burn wound was almost neatly healed, it was found that in the case of the burn wound that started treatment with the present invention, the wound wound was healed in a relatively fast time compared to the number of times of the start of treatment with the general treatment.
  • the wounds of the bedsores and burns with the present invention are cured in a considerably faster time than the general treatment, and the wounds are cleanly cleared with almost no scars on the wounds. I could see that.
  • the prior art is not only used as a hemostatic agent by adhering saline to collagen but in close contact with the wound surface, and there is an insufficient problem of promoting wound healing.
  • the present invention there was a problem that the relaxation effect was low and easily dried, so that the conventional problem could be solved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pour traiter les lésions cutanées. Dans la présente invention, de la glycérine contenant un extrait de plante est mélangée avec un collagène et appliquée sur une lésion cutanée. La glycérine appliquée sur la lésion cutanée détruit les bactéries infectieuses et autres contaminants grâce à une pression osmotique élevée qui permet de décharger un exsudat depuis l'intérieur de la peau vers la lésion cutanée. L'extrait de plante stimule le traitement de la lésion en neutralisant les enzymes protéolytiques qui détruisent la matrice intercellulaire, ce qui permet de régénérer la matrice et ainsi de stimuler la croissance cellulaire. L'ajout de collagène non seulement neutralise plus rapidement les collagénases, mais en le combinant avec la glycérine pour supprimer l'évaporation d'humidité et ainsi maintenir un état hydraté, apporte un effet de soulagement de la douleur, recouvre la lésion, et stimule l'effet de traitement de la lésion.
PCT/KR2016/009107 2015-08-19 2016-08-18 Composition pour le traitement de lésions cutanées Ceased WO2017030388A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201680019591.4A CN107427561A (zh) 2015-08-19 2016-08-18 皮肤伤口治疗组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0116661 2015-08-19
KR1020150116661A KR101649450B1 (ko) 2015-08-19 2015-08-19 피부 상처 치료조성물

Publications (2)

Publication Number Publication Date
WO2017030388A1 true WO2017030388A1 (fr) 2017-02-23
WO2017030388A9 WO2017030388A9 (fr) 2018-03-01

Family

ID=56874658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/009107 Ceased WO2017030388A1 (fr) 2015-08-19 2016-08-18 Composition pour le traitement de lésions cutanées

Country Status (3)

Country Link
KR (1) KR101649450B1 (fr)
CN (1) CN107427561A (fr)
WO (1) WO2017030388A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108125903A (zh) * 2018-01-19 2018-06-08 深圳光彩生命工程技术有限公司 一种新型干细胞复合因子抗衰老化妆品

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101904196B1 (ko) 2017-04-18 2018-10-04 이상철 피부 상처 치료 조성물
CN109364086B (zh) * 2018-11-28 2020-12-15 福建师范大学 高渗甘油预处理提高氨基糖苷类抗生素杀菌效率的方法
KR102292114B1 (ko) * 2020-11-13 2021-08-20 주식회사 피에프네이처 식물 복합 추출물을 유효성분으로 포함하는 피부 보습, 미세먼지 유발 염증 개선, 및 모공축소용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891359A (en) * 1988-12-08 1990-01-02 Johnson & Johnson Patient Care, Inc. Hemostatic collagen paste composition
KR20090060449A (ko) * 2006-10-13 2009-06-12 우루루 인코퍼레이티드 인시츄 형성된 하이드로겔 상처 드레싱 및 생체물질 그리고 그들의 사용
KR20100030031A (ko) * 2008-09-09 2010-03-18 한스바이오메드 주식회사 인체 피부재생용 분말의 제조방법
KR20110102811A (ko) * 2010-03-11 2011-09-19 이상철 상처치료용 조성물
KR20120015783A (ko) * 2010-08-13 2012-02-22 주식회사 셀랩 경피 흡수 투여용 하이드로겔 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1402749B1 (it) * 2010-10-28 2013-09-18 Indena Spa Composizioni per il trattamento di ulcere periferiche di varia origine
RU2683774C2 (ru) * 2012-03-14 2019-04-02 Изун Фармасьютикалс Корп. Новые способы и композиции для лечения заболевания
ITTO20130091A1 (it) * 2013-02-04 2014-08-05 Silvachimica S R L Composizione per la produzione di un materiale espanso elastico a base di tannini, e relativo procedimento.
CN103520708A (zh) * 2013-10-22 2014-01-22 易金阳 一种能促进创伤愈合、减少疤痕形成的组合物
CN103989828A (zh) * 2014-05-21 2014-08-20 海南生态美生物科技有限公司 一种促进伤口愈合的组合物及其制备方法
KR101768870B1 (ko) * 2015-04-13 2017-08-17 주식회사 래디안 백미 추출물의 지표성분인 시나프산 또는 이를 함유하는 백미 추출물을 함유하는 피부재생용 화장료 조성물 및 상처 치료용 약학 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891359A (en) * 1988-12-08 1990-01-02 Johnson & Johnson Patient Care, Inc. Hemostatic collagen paste composition
KR20090060449A (ko) * 2006-10-13 2009-06-12 우루루 인코퍼레이티드 인시츄 형성된 하이드로겔 상처 드레싱 및 생체물질 그리고 그들의 사용
KR20100030031A (ko) * 2008-09-09 2010-03-18 한스바이오메드 주식회사 인체 피부재생용 분말의 제조방법
KR20110102811A (ko) * 2010-03-11 2011-09-19 이상철 상처치료용 조성물
KR20120015783A (ko) * 2010-08-13 2012-02-22 주식회사 셀랩 경피 흡수 투여용 하이드로겔 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108125903A (zh) * 2018-01-19 2018-06-08 深圳光彩生命工程技术有限公司 一种新型干细胞复合因子抗衰老化妆品

Also Published As

Publication number Publication date
WO2017030388A9 (fr) 2018-03-01
CN107427561A (zh) 2017-12-01
KR101649450B1 (ko) 2016-08-18

Similar Documents

Publication Publication Date Title
CN102670929B (zh) 一种用于外伤愈合的组合物及其制备方法
US8426384B2 (en) Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate
WO2017030388A1 (fr) Composition pour le traitement de lésions cutanées
Santhanam et al. Bovine based collagen dressings in wound care management
CA2630147C (fr) Compositions pour l'interruption et l'inhibition de la reconstitution de film biologique de plaies
CN1194777C (zh) 一种人工皮肤及其制备方法和用途
RU2108114C1 (ru) Биологическая композиция для лечения ран "коллахит"
KR101904196B1 (ko) 피부 상처 치료 조성물
CN113648350A (zh) 一种食蟾虫水凝胶敷料的制备方法
Mukhopadhyay et al. Speciality dressings for managing difficult-to-heal wounds
US20140030365A1 (en) Compositions for the debridement, granulation and reepithelialization of wounds in man
Khattabi et al. Complete Healing and Short-term Treatment by Argania Honey Dressing in a Venous Leg Ulcer: A Case Report
US20080102106A1 (en) Wound Healing Composition Comprising Substances From Diptera Larvae
KR101607229B1 (ko) 말기름을 함유하는 상처 치료용 조성물
Pillay et al. Experimental Evaluation of Repair Process of Burn-Wounds Treated with 15 UMF Manuka Honey Yam Mun Fei,'AG Pillay and" Jamaludin Zainol
KR100289906B1 (ko) 피부용조성물
Wiśniewska-Wrona et al. Chitosan-based materials for wound healing and regeneration
KR20220144070A (ko) 계란 껍데기 분말을 유효 성분으로 함유하는 화상 치료용 조성물
KR20020087210A (ko) 상처치유 조성물
Bhattacharjee et al. A Technical Overview: Polymers for Wounds and Burns Dressing as Hydrogel Drug Delivery System
Grotte Honey as a Dressing for Wounds, Burns, and Ulcers
DAYARAMANI A Technical Overview: Polymers for Wounds and Burns Dressing as Hydrogel Drug Delivery System
FI20170117A1 (fi) Tulehtuneen ihon hoitovoiteen vaikuttavat aineet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16837330

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16837330

Country of ref document: EP

Kind code of ref document: A1